Cheng Wang

US Patent:

6708045, Mar 16, 2004

Filed:

Apr 7, 2000

Appl. No.:

09/545228

Inventors:

Winston Hong Lieu - Holmdel NJ
Cheng Wang - Belle Mead NJ
David Kiley - Brick NJ
Charles Chia-Yi Pai - Cupertino CA

Assignee:

Mobicom, Inc. - Holmdel NJ

International Classification:

H04B 138

US Classification:

455557, 455418, 455558

Abstract:

A wireless terminal is described whose software are more easily upgradable than many in the prior art. Furthermore, the first illustrative embodiment of the present invention is an arrangement in which a user can easily: (1) upgrade the software in a wireless terminal, (2) change the parameters affecting the operation of the wireless terminal, (3) enable and disable features and options on the wireless terminal, (4) install software modules onto the wireless terminal and remove them, (5) reconfigure the reconfigurable hardware on the wireless terminal, (6) extract performance data from the wireless terminal for analysis and testing of the wireless terminal, and (7) load contact information (e. g. , names and associated telephone numbers, etc. ) onto the wireless terminal.

US Patent:

7041682, May 9, 2006

Filed:

Jul 2, 2003

Appl. No.:

10/612176

Inventors:

Neng-Yang Shih - North Caldwell NJ, US
Steven Wang - Jersey City NJ, US
Gregory Reichard - Ann Arbor MI, US
Dong Xiao - Warren NJ, US
Cheng Wang - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/445
C07D 211/56

US Classification:

514326, 546207, 546208, 546209, 546210, 546212, 546214, 544124

Abstract:

Disclosed are NKantagonists having the formula:.

US Patent:

7049320, May 23, 2006

Filed:

Dec 17, 2002

Appl. No.:

10/321687

Inventors:

Sunil Paliwal - Scotch Plains NJ, US
Gregory A. Reichard - Ann Arbor MI, US
Cheng Wang - Summit NJ, US
Dong Xiao - Warren NJ, US
Neng-Yang Shih - North Caldwell NJ, US
Juan D. Arredondo - Montclair NJ, US
Michelle Laci Wrobleski - Whitehouse Station NJ, US
Anandan Palani - Bridgewater NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/44
C07D 221/20

US Classification:

514278, 546 16, 546 19

Abstract:

A NKantagonist having the formula (I),.

US Patent:

7354922, Apr 8, 2008

Filed:

Dec 1, 2005

Appl. No.:

11/291363

Inventors:

Dong Xiao - Warren NJ, US
Anandan Palani - Bridgewater NJ, US
Cheng Wang - Summit NJ, US
Xianhai Huang - Warren NJ, US
Sapna S. Shah - Jamesburg NJ, US
Ashwin U. Rao - Avenel NJ, US
Xiao Chen - Edison NJ, US
Sunil Paliwal - Monroe Township NJ, US
Neng-Yang Shih - Warren NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A01N 43/58
A01N 43/60
C07D 245/00
C07D 241/36
C07D 471/00

US Classification:

514249, 540460, 544349

Abstract:

A compound having the general structure shown in Formula (I):.

US Patent:

7498438, Mar 3, 2009

Filed:

Apr 6, 2005

Appl. No.:

11/100226

Inventors:

Dong Xiao - Warren NJ, US
Anandan Palani - Bridgewater NJ, US
Cheng Wang - King of Prussia PA, US
Neng-Yang Shih - Warren NJ, US
Gregory A. Reichard - Ann Arbor MI, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D 471/02
C07D 491/02

US Classification:

546116, 546118

Abstract:

A compound having the general structure shown in Formula 1:.

US Patent:

20060094720, May 4, 2006

Filed:

Dec 15, 2005

Appl. No.:

11/300848

Inventors:

Neng-Yang Shih - Warren NJ, US
Steven Wang - Jersey City NJ, US
Gregory Reichard - Ann Arbor MI, US
Dong Xiao - Warren NJ, US
Cheng Wang - Summit NJ, US

International Classification:

A61K 31/5377
A61K 31/454
A61K 31/453
C07D 409/02
C07D 413/02

US Classification:

514235200, 514317000, 514326000, 544128000, 546207000, 546211000, 546223000

Abstract:

Disclosed are NKantagonists having the formula: Also disclosed are methods for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough, using the compounds of formula (I).

US Patent:

20200196925, Jun 25, 2020

Filed:

Mar 5, 2020

Appl. No.:

16/810183

Inventors:

- New York NY, US
- Iowa City IA, US
Junyi Shang - New York NY, US
Zhixing Zhang - New York NY, US
Xuejun Wang - New York NY, US
Jaeyoung Yang - New York NY, US
Cheng Wang - New York NY, US
Pavana G. Rotti - Iowa City IA, US
John F. Engelhardt - Iowa City IA, US
Zhuang Hao - New York NY, US

Assignee:

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
DEPARTMENT OF ANATOMY AND CELL BIOLOGY - UNIVERSITY OF IOWA - Iowa City IA

International Classification:

A61B 5/145
G01N 33/74
G01N 27/414
H01L 21/02
H01L 29/16
H01L 23/38
A61B 5/1491
A61B 5/1477
A61B 5/00
H01L 51/05

Abstract:

A microdevice for monitoring a target analyte is provided. The microdevice can include a field effect transistor comprising a substrate, a gate electrode, and a microfluidic channel including graphene. The microfluidic channel can be formed between drain electrodes and source electrodes on the substrate. The microdevice can also include at least one aptamer functionalized on a surface of the graphene. The at least one aptamer can be adapted for binding to the target analyte. Binding of the target analyte to the at least one aptamer can alter the conductance of the graphene.

US Patent:

20200154684, May 21, 2020

Filed:

Jun 27, 2018

Appl. No.:

16/625168

Inventors:

- Tarrytown NY, US
Viktoria Gusarova - Pleasantville NY, US
Cheng Wang - White Plains NY, US
Christos Kyratsous - Irvington NY, US
Terra Potocky - Dobbs Ferry NY, US
Katherine Cygnar - New York NY, US
Joel Martin - Putnam Valley NY, US

International Classification:

A01K 67/027
A61K 49/00
C07K 14/705

Abstract:

Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.